Vandetanib
Inquiry
| Post Date: | Nov 24,2013 |
| Expiry Date: | May 23,2014 |
| Detailed Description: | Cas No. :443913-73-3 Miracpharma has developed many pharmaceutical projects with categories of anticancer, antithrombotic, antiviral, anti-inflammatory and antibiotic, etc (see www.miracpharma.com). we have applied over 70 patents include about 100 new compounds(new CAS RN) and a lot of new processes of over 30 kinds of APIs and intermediates. Using our strategy of patent protection, the product is good quality, low expenditure, convenient process and environment-friendly. We are looking for appropriate manufacturers of API or intermediates who can exploitation of our patents by mean of patent license or technology transfer. We are also looking for farseeing investors and copartners who can discuss patent license and assignment, co-operation and business, join hands and march forwards for the greater prosperous future with us. |
| CAS Registry Number: | 443913-73-3 |
| Synonyms: | ;4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline;Vandetanib, Zactima, ZD6474;N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazolin-4-amine;AZD-6474;ZD-6474;N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine; |
| Molecular Formula: | C22H24BrFN4O2 |
| Molecular Weight: | 475.35 |
| Molecular Structure: | 
|
| Company: | Suzhou MiracPharma Technology Co., Ltd [ China ] |
| Contact: | X.Xu |
| Tel: | +86 18262008418 |
| Fax: | - |
| Email: | manager@miracpharma.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
